Related Experiment Video
Updated: Mar 1, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Is There a Dose-Response Relationship between Tea Consumption and All-Cause, CVD, and Cancer Mortality?
Yi Yan1, Xuemei Sui2, Bin Yao3
1a Sports Science College, Beijing Sport University , Beijing , CHINA.
Background:
A small change in tea consumption at population level could have large impact on public health. However, the health benefits of tea intake among Americans are inconclusive.
Objective:
To evaluate the association between tea consumption and all-causes, cardiovascular disease (CVD) and cancer mortality in the Aerobics Center Longitudinal study (ACLS).
Methods:
11808 participants (20-82 years) initially free of CVD and cancers enrolled in the ACLS and were followed for mortality. Participants provided baseline self-report of tea consumption (cups/day). During a median follow-up of 16 years, 842 participants died. Of others, 250 died from CVD, and 345 died from cancer, respectively. A Cox proportional hazard model was used to produce hazard ratio (HR) and 95% confidence interval (CI).
Results:
Compared with participants consuming no tea, tea drinkers had a survival advantage ( Log-2 = 10.2, df = 3, P = 0.017); however, the multivariate hazard ratios (HRs) of all-cause mortality for those drinking 1-7, 8-14, and >14 cups/week were 0.95 (95% CI, 0.81-1.12), 1.00 (95% CI, 0.82-1.22), and 0.98 (95% CI, 0.76-1.25), respectively (P for linear trend = 0.83). The multivariate HR were 1.16 (95% CI, 0.86-1.56), 1.22 (95% CI, 0.85-1.76), and 0.94 (95% CI, 0.56-1.54) for CVD mortality (P for linear trend = 0.47), and 0.97 (95% CI, 0.75-1.25), 0.85 (95% CI, 0.60-1.16), and 0.94 (95% CI, 0.64-1.38) for cancer mortality (P for trend = 0.62).
Conclusions:
There were week or null relationships between tea consumption and mortality due to all-cause, CVD disease or cancer were observed in ACLS.
Related Concept Videos
Dose Response Curve: Conventional Versus Nonmonotonic
Dose-Response Relationship: Overview
Cancer Prevention
Some...
Dose-Response Relationship: Potency and Efficacy
Cancer Survival Analysis
Dose-Response Relationship: Selectivity and Specificity

